EA202191470A1 - Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения - Google Patents

Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения

Info

Publication number
EA202191470A1
EA202191470A1 EA202191470A EA202191470A EA202191470A1 EA 202191470 A1 EA202191470 A1 EA 202191470A1 EA 202191470 A EA202191470 A EA 202191470A EA 202191470 A EA202191470 A EA 202191470A EA 202191470 A1 EA202191470 A1 EA 202191470A1
Authority
EA
Eurasian Patent Office
Prior art keywords
granulocyte
stimulating factor
application
antibodies specifically
specifically recognizing
Prior art date
Application number
EA202191470A
Other languages
English (en)
Inventor
Пинся Чжу
Жань У
Циншуан Чжан
Цюнь Хуан
Original Assignee
Стейдсон (Бейджин) Биофармасьютикалз Ко., Лтд.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Стейдсон (Бейджин) Биофармасьютикалз Ко., Лтд. filed Critical Стейдсон (Бейджин) Биофармасьютикалз Ко., Лтд.
Publication of EA202191470A1 publication Critical patent/EA202191470A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/1034—Isolating an individual clone by screening libraries
    • C12N15/1037—Screening libraries presented on the surface of microorganisms, e.g. phage display, E. coli display
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Virology (AREA)

Abstract

Согласно настоящей заявке предложены антитела, в том числе их антигенсвязывающий фрагмент, которые специфично распознают рецептор гранулоцитарно-макрофагального колониестимулирующего фактора (GM-CSFR). Также предложены способы получения и применения этих антител.
EA202191470A 2018-11-27 2019-11-25 Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения EA202191470A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2018117581 2018-11-27
PCT/CN2019/120545 WO2020108423A1 (en) 2018-11-27 2019-11-25 Antibodies specifically recognizing granulocyte-macrophage colony stimulating factor receptor alpha and uses thereof

Publications (1)

Publication Number Publication Date
EA202191470A1 true EA202191470A1 (ru) 2021-09-07

Family

ID=70853745

Family Applications (1)

Application Number Title Priority Date Filing Date
EA202191470A EA202191470A1 (ru) 2018-11-27 2019-11-25 Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения

Country Status (13)

Country Link
US (1) US20230002496A1 (ru)
EP (1) EP3902835A4 (ru)
JP (2) JP7290725B2 (ru)
KR (1) KR102655193B1 (ru)
CN (2) CN113348179A (ru)
AU (1) AU2019388584B2 (ru)
BR (1) BR112021009709A2 (ru)
CA (2) CA3120729A1 (ru)
EA (1) EA202191470A1 (ru)
PH (1) PH12021551195A1 (ru)
SG (1) SG11202105403XA (ru)
WO (1) WO2020108423A1 (ru)
ZA (1) ZA202103596B (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3202339A1 (en) * 2020-12-18 2022-06-23 Mei Jang Protein compositions and methods for producing and using the same
WO2023138499A1 (zh) * 2022-01-20 2023-07-27 舒泰神（北京）生物制药股份有限公司 一种特异性地识别粒细胞-巨噬细胞集落刺激因子受体的抗体制剂及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2423230T3 (pl) * 2006-03-27 2013-10-31 Medimmune Ltd Element wiążący dla receptora GM-CSF
CN103193882B (zh) * 2013-03-29 2014-11-05 浙江大学 胚胎干细胞特异性标志物GM-CSFRα及其应用

Also Published As

Publication number Publication date
BR112021009709A2 (pt) 2021-10-19
EP3902835A4 (en) 2022-08-17
AU2019388584A1 (en) 2021-06-10
US20230002496A1 (en) 2023-01-05
CA3183309A1 (en) 2020-06-04
JP2023011887A (ja) 2023-01-24
SG11202105403XA (en) 2021-06-29
ZA202103596B (en) 2022-04-28
KR102655193B1 (ko) 2024-04-04
CA3120729A1 (en) 2020-06-04
WO2020108423A1 (en) 2020-06-04
AU2019388584B2 (en) 2024-02-15
CN116003597A (zh) 2023-04-25
EP3902835A1 (en) 2021-11-03
CN113348179A (zh) 2021-09-03
PH12021551195A1 (en) 2021-10-25
KR20210129631A (ko) 2021-10-28
JP2022510171A (ja) 2022-01-26
JP7290725B2 (ja) 2023-06-13

Similar Documents

Publication Publication Date Title
MX2020012797A (es) Anticuerpos biespecificos anti-pvrig/anti-tigit y métodos de uso.
CY1122456T1 (el) Μονοκλωνικα αντισωματα εναντιον παραγοντα 15 αυξησης και διαφοροποιησης (gdf-15), και χρησεις αυτων για θεραπευτικη αγωγη καρκινικης καχεξιας και καρκινου
EA201792467A1 (ru) Гетеродимерные антитела, которые связывают cd3 и опухолевые антигены
MX2022014695A (es) Anticuerpos anti-gitr y sus usos.
EA202092907A1 (ru) Мультиспецифические связывающие белки и их усовершенствования
EA201790339A1 (ru) Комбинированные препараты с антителами к cd40
EA202092605A1 (ru) Антитела к ил-11ra
MX2021008958A (es) Proteínas de unión a antígeno del receptor gamma anti-il2.
MX2020013428A (es) Anticuerpos monoclonales contra inmunoglobulina de celulas t y molecula que contiene dominio de mucina-3 (tim-3) humana.
EA202191769A1 (ru) Тубулизины и конъюгаты белок-тубулизин
CO2022004797A2 (es) Anticuerpos anti-klk7, anticuerpos anti-klk5, anticuerpos multiespecíficos anti-klk5/klk7 y métodos de uso
EA202191470A1 (ru) Антитела, специфично распознающие рецептор-альфа гранулоцитарно-макрофагального колониестимулирующего фактора, и их применения
EA202092508A1 (ru) Составы на основе антител к pd-l1 человека
MX2021002750A (es) Anticuerpos anti-tnfrsf9 y usos de los mismos.
MX2020010104A (es) Conjugados de farmaco-anticuerpo anti-antigeno de membrana especifico de prostata (psma) humanizado.
PH12020552270A1 (en) Anti-steap1 antigen-binding protein
CR20230581A (es) Anticuerpos anti-CCR8 y usos de los mismos
EA201992315A1 (ru) Композиции и способы для лечения рака легкого
MX2021010254A (es) Conjugados de anticuerpo-farmaco que comprenden anticuerpos anti-tm4sf1 y metodos de uso de los mismos.
EA201992348A1 (ru) АНТИГЕН-СВЯЗЫВАЮЩИЕ БЕЛКИ, ВЗАИМОДЕЙСТВУЮЩИЕ С Jagged1
MX2022000379A (es) Anticuerpos que se unen a celulas cancerosas yque dirigen radionucleidos a dichas celulas.
CR20200623A (es) Conjugados de fármaco y anticuerpo anti-sez6 y métodos de uso
EA202092122A1 (ru) Антитела против tip-1 и их применения
EA202092947A1 (ru) Анти-pvrig/анти-tigit биспецифические антитела и способы их применения
EA202090929A1 (ru) Антитела, активируемые антитела, биспецифические антитела и биспецифические активируемые антитела и способы их применения